Moclobemide

Suppliers

Names

[ CAS No. ]:
71320-77-9

[ Name ]:
Moclobemide

[Synonym ]:
4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide
Moclamide
moclbemide
Manefix
Moclobemide
aurorix
4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide
4-Chloro-N-[2-(4-morpholinyl)ethyl]benzamide
MFCD00865388
Moclobemidum
MODOBEMDE
ro11-1163
Moclaime
Benzamide, 4-Chloro-N-(2-(4-morpholinyl)ethyl)-
p-Chloro-N-(2-morpholinoethyl)benzamide
UNII-PJ0Y7AZB63
manerix
Benzamide, 4-chloro-N-[2-(4-morpholinyl)ethyl]-
Moclamine

Chemical & Physical Properties

[ Density]:
1.2±0.1 g/cm3

[ Boiling Point ]:
447.7±40.0 °C at 760 mmHg

[ Melting Point ]:
137°C

[ Molecular Formula ]:
C13H17ClN2O2

[ Molecular Weight ]:
268.739

[ Flash Point ]:
224.6±27.3 °C

[ Exact Mass ]:
268.097870

[ PSA ]:
41.57000

[ LogP ]:
0.84

[ Vapour Pressure ]:
0.0±1.1 mmHg at 25°C

[ Index of Refraction ]:
1.550

[ Storage condition ]:
Room temp

MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
CV2462000
CHEMICAL NAME :
Benzamide, 4-chloro-N-(2-(4-morpholinyl)ethyl)-
CAS REGISTRY NUMBER :
71320-77-9
LAST UPDATED :
199803
DATA ITEMS CITED :
6
MOLECULAR FORMULA :
C13-H17-Cl-N2-O2
MOLECULAR WEIGHT :
268.77

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
5 mg/kg/5W-I
TOXIC EFFECTS :
Skin and Appendages - hair
REFERENCE :
HUPSEC Human Psychopharmacology. (John Wiley & Sons Ltd., Baffins Lane, Chichester, W.Sussex PO19 1UD, United Kingdom) V.1- 1986- Volume(issue)/page/year: 12,81,1997
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
19 mg/kg
TOXIC EFFECTS :
Behavioral - sleep Behavioral - hallucinations, distorted perceptions Gastrointestinal - nausea or vomiting
REFERENCE :
JCLPDE Journal of Clinical Psychiatry. (Physicians Postgraduate Press, Inc., POB 240008, Memphis, TN 38124) V.39- 1978- Volume(issue)/page/year: 47,438,1986
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
66 mg/kg/11D-I
TOXIC EFFECTS :
Vascular - BP elevation not characterized in autonomic section
REFERENCE :
LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 346,1032,1995
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
12600 mg/kg/14D-I
TOXIC EFFECTS :
Blood - thrombocytopenia Blood - leukemia Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 347,1329,1996
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
707 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4210754
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
591 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
EJMCA5 European Journal of Medicinal Chemistry--Chimie Therapeutique. (Editions Scientifiques Elsevier, 29 rue Buffon, F-75005, Paris, France) V.9- 1974- Volume(issue)/page/year: 31,909,1996

Safety Information

[ Symbol ]:

GHS05, GHS07

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H302-H315-H318-H335

[ Precautionary Statements ]:
P261-P280-P305 + P351 + P338

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves

[ Hazard Codes ]:
Xn: Harmful;

[ Risk Phrases ]:
R22

[ Safety Phrases ]:
S26-S39

[ RIDADR ]:
3249

[ RTECS ]:
CV2462000

[ Packaging Group ]:
III

[ Hazard Class ]:
6.1(b)

Synthetic Route

Precursor & DownStream

Precursor

  • 2-Morpholinoethanamine
  • 4-Bromochlorobenzene
  • carbon monoxide
  • 4-Chlorobenzoic acid
  • 4-Chlorobenzaldehyde
  • 1-Chloro-4-iodobenzene
  • p-chloro-N-(2-morpholinoethyl)-thiobenzamide hydrochloride
  • morpholine
  • 4-chloro-N-(2-chloroethyl)benzamide

DownStream

Articles

Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice.

Prog. Neuropsychopharmacol. Biol. Psychiatry 39(1) , 31-9, (2012)

Monoamine oxidase (MAO) inhibitors were the first antidepressant drugs to be prescribed and are still used today with great success, especially in patients resistant to other antidepressants. In this ...

[Serotonin syndrome in the course of drug-poisoning--case presentation].

Prz. Lek. 68(8) , 523-6, (2011)

Serotonin syndrome is caused by excess serotonin in the central nervous system. It usually occurs as adverse drug-therapy (neuroleptic agents, monoamine oxidase inhibitors, serotonin reuptake inhibito...

[Obstructive sleep apnoea syndrome as the cause of atypical depression].

Fortschr. Neurol. Psychiatr. 79(9) , 531-4, (2011)

Sleep apnoea is a common disorder presenting with somatic comorbidities and psychiatric symptoms. This case report describes a 43-year-old man with an organic depressive disorder due to obstructive sl...


More Articles


Related Compounds

  • Moclobemide N-Oxide
  • 4-((Cyclohexylamino)methyl)benzoic acid hydrochloride
  • 1-[(2,4-Dichlorophenyl)methyl]-N-(1,1-dimethylethyl)-2-methyl-1H-indole-3-methanamine
  • 2-Methoxy-6-(pyrazol-1-yl)-benzonitrile
  • 1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-5-(3-iodophenyl)-3-methyl-, (S)-
  • (4-Methyl-tetrahydro-furan-2-yl)-methanol
  • N-(1-cyanocyclopentyl)-2-[4-(4-fluorobenzenesulfonyl)-1,4-diazepan-1-yl]acetamide
  • 2-{[5-ethyl-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)phenyl]formamido}butanoic acid
  • 4-tert-butyl 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl) morpholine-2,4-dicarboxylate
  • 4,5,6,7-Tetrahydrobenzo[d]isoxazole-3-carbaldehyde
  • tert-Butyl-DL-alanine